Aquestive(AQST) - 2025 Q3 - Quarterly Results

If approved by the United States Food and Drug Administration (FDA), Anaphylm would be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis. Aquestive believes that Anaphylm's needle-free, portable, and easy-to-administer formulation can help overcome barriers to epinephrine use and improve patient compliance in emergency situations. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Warren, ...